3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
20
Rectal Neoplasms
11
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Stomach Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Liver Neoplasms
2
Recurrence
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oligometastatic Gastric Adenocarcinoma
1
Neuroendocrine Tumors
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Neoplasm Recurrence, Local
1
Margins of Excision
1
Locally Advanced Rectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
13
Cisplatin
11
durvalumab
7
Oxaliplatin
5
Capecitabine
5
Fluorouracil
4
S 1 (combination)
3
Leucovorin
3
Irinotecan
3
zanidatamab
2
gemcitabine-oxaliplatin regimen
2
Trastuzumab
2
trastuzumab deruxtecan
1
pembrolizumab
1
niraparib
1
neratinib
1
ivosidenib
1
futibatinib
1
envafolimab
1
encorafenib
1
binimetinib
1
becatecarin
1
Tegafur
1
Pancreaticojejunostomy
1
NUC-1031
1
Folfox protocol
1
Drug Therapy
1
Chemotherapy, Adjuvant
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Biliary Tract Neoplasms
×
Folfox protocol
×
Clear all
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled